Molecular Partners AG (XSWX:MOLN) Short Ratio


XSWX:MOLN Molecular Partners AG XSWX:MOLN
29 GF Score
Price CHF3.20
GF Value CHF0.37
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Molecular Partners AG Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XSWX:MOLN
29GF Score
Molecular Partners AG XSWX:MOLN
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Molecular Partners AG (XSWX:MOLN) Overvalued in 2026?

Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued. The current stock price of CHF3.20 is trading 764.9% above its estimated GF Value™ of CHF0.37. GuruFocus considers Molecular Partners AG to be Significantly Overvalued.

Key valuation signals for XSWX:MOLN:

  • Short Ratio:
  • GF Value™: CHF0.37 vs. price of CHF3.20 (764.9% above fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the XSWX:MOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Molecular Partners AG Business Description

Address Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
29GF Score

Get the complete analysis for XSWX:MOLN

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF3.20
Price
CHF0.37
GF Value